Exelixis Inc

Important Upgrade Notice:

At 9 pm Central, Sunday 2/16/2020, we launched the following tools as Phase One of our Premium Plus service (full service package still under development):

1) Customizable Scrolling Ticker
2) Portfolio Manager
3) Stock-specific News & Trading Email Alert Notifications

These products are immediately available to Precious Metal & Gemstone Patrons.

To watch a tutorial on the "regular" site, click here. On "premium," click here.

Links: Y! EXEL chart/quote @ Y! F

EXEL / Message Board

Written By On Topic Only -- All Messages

Hide Replies

Keyword
Subject

Between			and
Rec'd By

Authored By
Minimum Recs

MSG #	SUBJECT	TYPE	AUTHOR	SENTIMENT	RECS	DATE POSTED
23850	Cabozantinib in patients with advanced Ewing sarcoma or osteosarcoma (CABONE): a multicentre, single-arm, phase 2 trial	GN	Pacific		3	2/17/2020 8:45:19 PM

23849	Re: Asco-GU: confirmation for Seattle and a reminder for Mirati	GN	JoeFlow		3	2/17/2020 7:40:53 PM

23848	OT: NLRP3	GN	Pacific		1	2/17/2020 7:23:37 PM

23847	Re: Asco-GU: confirmation for Seattle and a reminder for Mirati	GN	tomn		3	2/17/2020 6:30:04 PM

23846	Re: Dr. Pal on Cohort Findings of COSMIC-021 Trial in mCRPC	GN	mathlover		1	2/17/2020 5:34:35 PM

23845	Re: Asco-GU: confirmation for Seattle and a reminder for Mirati	GN	alias geo		1	2/17/2020 3:55:10 PM

23844	Re: Dr. Pal on Cohort Findings of COSMIC-021 Trial in mCRPC	GN	erniewerner		4	2/17/2020 2:52:07 PM

23843	The COSMIC-021 mCRPC cohort - Neeraj Agarwal	GN	Pacific		2	2/17/2020 1:28:28 PM

23842	Tanya Dorff, MD, elaborates on data investigating atezolizumab and cabozantinib in prostate cancer	GN	Pacific		2	2/17/2020 1:26:37 PM

23841	Emerging Therapies in Renal Cell Carcinoma	GN	Pacific		1	2/17/2020 1:20:40 PM


	About Us • Contact Us • Follow Us on Twitter • Members Directory • Help Center • Advertise Not a member yet? What are you waiting for? Create Account Want to contribute? Support InvestorVillage by donating © 2003-2019 Investorvillage.com. All rights reserved. User Agreement